2024-514490-22-01招募中3 期
Pharmacological treatment of compulsive sexual behaviour disorder
Centrum Medyczne Ksztalcenia Podyplomowego1 个研究点 分布在 1 个国家目标入组 410 人开始时间: 2025年2月24日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 410
- 试验地点
- 1
- 主要终点
- Scores obtained on the CSBD-19 scale
研究概览
简要总结
Comparison of the effects of treatment with escitalopram, naltrexone, and combined treatment (escitalopram plus naltrexone) or placebo on reducing the severity of symptoms of CSBD.
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Male gender and age 18-60 years
- •Signed informed consent form for participation in the study and consent to the processing of personal data
- •Declared willingness to participate in the procedures included in the study protocol
- •Subjective sense of loss of control over one's sexual behavior (e.g., viewing pornography, masturbation, or use of paid sexual services, etc.),
- •Seeking specialized help/therapy including pharmacotherapy for perceived symptoms or consequences of the symptoms,
- •Fulfilling the criteria for the diagnosis of CSBD according to the ICD-11 diagnostic guidelines (WHO, 2022): 1) A persistent pattern of inability to control intense, repetitive sexual impulses or arousals resulting in repetitive sexual behavior manifested by one or more of the following: (a) repeated sexual activities become the focal point of the person's life to the point of neglecting health and personal needs or other interests, activities and responsibilities (b) the person has made repeated unsuccessful attempts to control or significantly reduce repetitive sexual behavior (c) the person continues to engage in repeated sexual behavior despite its negative consequences (e.g., relationship conflict caused by the sexual behavior, financial or legal consequences, negative health effects) or derives little or no satisfaction from it (d) the person continues to engage in repeated sexual behavior even despite deriving little or no satisfaction from it. 2) The pattern of inability to control intense sexual impulses or arousals and the resulting repetitive sexual behavior manifests itself over an extended period of time (6 months or longer) 3) The pattern of inability to control intense sexual impulses or arousals and the resulting repetitive sexual behavior is not caused by another mental disorder (e.g., an episode of mania) or other medical condition, or the effects of a substance or drug. 4) The pattern of inability to control intense sexual impulses or urges and the resulting repetitive sexual behavior causes clinically significant suffering or significant impairment of personal, family, social, educational, occupational or other important spheres of functioning. Suffering that is related to moral judgments and disapproval of sexual impulses, motives or behavior is not sufficient to meet this condition
- •Achieving a score of 50 points or higher on the CSBD-19 questionnaire
- •Declared adherence to rules related to the use of contraception and exposure of a partner who could potentially become pregnant to the drug (means the use of a male condom and a second acceptable method of contraception of high effectiveness during the period of taking the test substance and for a period of 100 days after the end of taking the test substance if engaging in sexual relations with a partner who could potentially become pregnant and 7 days if the partner is pregnant)
排除标准
- •Co-occurrence of mania or bipolar affective disorder, moderate or severe depression episode, psychotic disorders, obsessive-compulsive disorder or cognitive impairment (dementia, mental retardation) according ro ICD-10 diagnostic guidelines (WHO, 2022)
- •Any laboratory result deviating from normal values (laboratory norm) will be analyzed on an individualized basis in conjunction with the participant's clinical condition and medical history. Laboratory deviations that are the basis for the decision not to start or withhold pharmacotherapy, and thus discontinue the patient's participation in the study. 1)aspartate aminotrasferase (AST), alanine aminotransferase (ALT) - activity exceeding 3 times the upper limit of normal 2)hemoglobin < 10 g/dL, 3)leukocytes <3000/µL, 4)platelets <100,000/µL, 3)fasting glucose > 120 mg%. 4)creatinine - increase in concentration exceeding 1.5 times the upper limit of normal 5)eGFR ≤ 50 ml/min/1.73m2 6)sodium - hyponatremia < 126 mmol/L or hypernatremia > 150 mmol/L, 7)potassium - hypokalemia ≤ 3 mmol/L, hyperkalemia ≥ 5.9 mmol/L.
- •Current use of antidepressant, anti-anxiety, antipsychotic or mood-stabilizing medications
- •Current use of psychotherapy or other psychological support
- •Clinically significant neurological disorders reported in the medical history
- •Current psychoactive substance dependence, compulsive gambling
- •Positive drug test result
- •Any medical contraindication to the use of escitalopram or naltrexone hydrochloride (according to summary of product characteristics)
- •Use of other drugs that have clinically significant or pharmacokinetic interactions with the investigational medicinal products
- •Other conditions that, in the opinion of the investigator, constitute significant contraindications to participation in the clinical trial, e.g. inability to participate in all study procedures including cognitive impairment to the extent that it is impossible to understand the study procedures and participate in the procedures
结局指标
主要结局
Scores obtained on the CSBD-19 scale
Scores obtained on the CSBD-19 scale
Scores obtained on the BPS scale
Scores obtained on the BPS scale
Frequency of compulsive sexual behavior measured by patient diary data.
Frequency of compulsive sexual behavior measured by patient diary data.
The severity of the perceived “desire” for compulsive sexual behavior
The severity of the perceived “desire” for compulsive sexual behavior
次要结局
- Scores obtained on the HADS scale.
- Scores obtained on the DERS-SF scale.
- Scores obtained on the IIEF-15 scale.
- Scores obtained on the BIS scale.
- Responsiveness to erotic stimulus cues measured by behavioral performance (reaction time and correctness of performance) in the Incentive Delay Task
- Reactivity to cues of erotic stimuli measured by neuronal indices (amplitude of evoked potentials in EEG) in the Incentive Delay Task
- Scores obtained on the CSBD-19 scale
- Scores obtained on the BPS scale
- Frequency of compulsive sexual behavior measured by patient diary data.
- The severity of the perceived “desire” for compulsive sexual behavior.
- Scores obtained on the CSBD-DI scale.
研究者
Ryszard Gellert
Scientific
Centrum Medyczne Ksztalcenia Podyplomowego
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
A pilot study to evaluate the possible use and effectiveness of an opiate antagonist for treatment of hypersexual disorder (sex abuse)Hypersexual disorderMedDRA version: 20.0Level: PTClassification code 10066364Term: HypersexualitySystem Organ Class: 10037175 - Psychiatric disordersEUCTR2018-001049-15-SEANOVA (Andrologi, Sexualmedicin, Transmedicin) Karolinska Universitetssjukhuset och Umeå Universitet20
已完成
2 期
Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Maintenance TherapyBinge-Eating DisorderObesityNCT03047005Yale University68
招募中
3 期
BACLOFEN FOR IMPROVING BENZODIAZEPINE TITRATION IN BENZODIAZEPINE DEPENDENCE. BABET2022-502307-30-00Hospices Civils De Lyon93
进行中（未招募）
不适用
Escitalopram and the Risk of Serious Adverse EventsNCT07274241London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's12,145
已完成
2 期
Double-Blind Naltrexone in Compulsive Sexual BehaviorCompulsive Sexual BehaviorNCT00467558University of Minnesota7